Design of Thymidylate Synthase Inhibitors Using Protein Crystal Structures: The Synthesis and Biological Evaluation of a Novel Class of 5-Substituted Quinazolinones

Journal of Medicinal Chemistry

Volumn 36, Issue 6, 1993, Pages 733-746

  Webber, Stephen E ^a   Bleckman, Ted M ^a   Attard, John ^a   Deal, Judith G ^a   Kathardekar, Vinit ^a   Welsh, Katherine M ^a   Webber, Stephanie ^a   Janson, Cheryl A ^a   Matthews, David A ^a   Smith, Ward W ^a   Freer, Stephan T ^a   Jordan, Steven R ^a   Bacquet, Russell J ^a   Howland, Eleanor F ^a   Booth, Carol L J ^a   Ward, Robert W ^a   Hermann, Steven M ^a   White, Jennifer ^a   Morse, Cathy A ^a   Hilliard, Jill A ^a   Bartlett, Charlotte A ^a   more..

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4(3H) QUINAZOLINONE DERIVATIVE; ANTINEOPLASTIC AGENT; FLOXURIDINE PHOSPHATE; THYMIDYLATE SYNTHASE;

ANIMAL CELL; ARTICLE; CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0027403420     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00058a010     Document Type: Article

References (62)

1. Berman, E. M.; Werbel, L. M. The Renewed Potential for Folate Antagonists in Contemporary Cancer Chemotherapy. J. Med. Chem. 1991, 34, 479–485.
2. Douglas, K. T. The Thymidylate Synthesis Cycle and Anticancer Drugs. Med. Res. Rev. 1987, 7, 441–475.
3. Chabner, B. A. Nucleoside Analogues. In Cancer and Chemotherapy, 3; Crooke, S. T., Prestayko, A. W., Eds.; Academic Press: New York, 1981; Part I, pp 9–15.
4. Sweeny, D. J.; Diasio, R. B. Toxicity of Antimetabolites. In The Toxicity of Anticancer Drugs; Powis, G., Hacker, M. P., Eds.; Pergamon Press: New York, 1991; Chapter 5, pp 68–72.
5. Myers, C. E. The Pharmacology of Fluoropyrimidines. Pharmacol. Rev. 1981, 33, 1–15.
6. Maybaum, J.; Ullman, B.; Mandel, H. G.; Day, J. L.; Sadee, W. Regulation of RNA- and DNA-Directed Actions of 5-Fluoropyrimidines in Mouse T-Lymphoma (S-49) Cells. Cancer Res. 1980, 40, 4209–4215.
7. Wilkinson, D. S.; Tlsty, T. D.; Hanas, R. J. The Inhibition of Ribosomal RNA Synthesis and Maturation in Novikoff Hepatoma Cells by 5-Fluorouridine. Cancer Res. 1975, 35, 3014–3020.
8. Jones, T. R.; Calvert, A. H.; Jackman, A. L.; Brown, S. J.; Jones, M.; Harrap, K. R. A Potent Antitumor Quinazoline Inhibitor of Thymidylate Synthetase: Synthesis, Biological Properties and Therapeutic Results in Mice. Eur. J. Cancer 1981, 17, 11.
9. Marsham, P. R.; Hughes, L. R.; Jackman, A. L.; Hayter, A. J.; Oldfield, J.; Wardleworth, J. M.; Bishop, J. A. M.; O'Connor, B. M.; Calvert, A. H. Quinazoline Antifolate Thymidylate Synthase Inhibitors: Heterocyclic Benzoyl Ring Modifications. J. Med. Chem. 1991, 34, 1594–1605.
10. Newell, D. R.; Siddik, Z. H.; Calvert, A. H.; Jackman, A. L.; Alison, D. L.; McGhee, K. G.; Harrap, K. R. Pharmacokinetic and Toxicity Studies of CB 3717. Proc. Am. Assoc. Cancer Res. 1982, 23, 181.
11. Newell, D. R.; Alison, D. L.; Calvert, A. H.; Harrap, K. R.; Jarman, M.; Jones, T. R.; Manteuffel-Cymborowska, M.; O'Connor, P. Cancer Treat. Rep. 1986, 70, 971–979.
12. 10-Propargyl-5,8-Dideazafolate (DMPDDF) and Related Compounds. Proc. Am. Assoc. Cancer Res. 1989, 30, 476.
13. Henderson, G. B.; Strauss, B. P. Characteristics of a Novel Transport System for Folate Compounds in Wild-Type and Methotrexate-Resistant L1210 Cells. Cancer Res. 1990, 50, 1709–1714.
14. Fry, D. W.; Jackson, R. C. Membrane Transport Alterations as a Mechanism of Resistance to Anticancer Agents. Concer Surv. 1986, 5, 47–49.
15. Jackman, A. L.; Kelland, L. R.; Brown, M.; Gibson, W.; Kimbell, R.; Aheme, W.; Judson, I. R. ICI D1694 Resistant Cell Lines. Proc. Am. Assoc. Cancer Res. 1992, 33, 406.
16. Jackman, A. L.; Taylor, G. A.; Moran, R.; Bishop, J. A. M.; Bisset, G.; Pawelczak, K.; Balmanno, K.; Hughes, L. R.; Calvert, A. H. Biological Properties of 2-Desamino-2-Sub8tituted-5,8-Deazafolates that Inhibit Thymidylate Synthase (TS). Proc. Am. Assoc. Cancer Res. 1988, 29, 287.
17. Jackman, A. L.; Gibson, W.; Stephens, T. C.; Boyle, F. T. Polyglutamation of the Thymidylate Synthase (TS) Inhibitor, ICI D1694. Proc. Am. Assoc. Cancer Res. 1992, 33, 406.
18. Jackman, A. L.; Taylor, G. A.; Gibson, W.; Kimbell, R.; Brown, M.; Calvert, A. H.; Judson, I. R.; Hughes, L. R. ICI D1694, a Quinazoline Antifolate Thymidylate Synthase Inhibitor That is a Potent Inhibitor of L1210 Tumor Cell Growth In Vitro and In Vivo: A New Agent for Clinical Study. Cancer Res. 1991, 51, 5579–5586.
19. 10-Propargyl-5,8-dideazafolic Acid, CB3717, in Organs of Ehrlich Ascites Carcinoma-Bearing Mice. In Chemistry and Biology of Pteridines; Cooper, B. A., Whitehead, V. M., Eds.; Walter de Gruyter: Berlin, 1986; pp 993–996.
20. 10-Propargyl-5,8-Dideazafolic Acid (CB3717) Polyglutamates in L1210 Cells In Vitro. Biochem. Pharmacol. 1988, 37, 4047–4054.
21. McNamara, D. J.; Berman, E. M.; Fry, D. W.; Werbel, L. M. Potent Inhibition of Thymidylate Synthase by Two Series of Nonclassical Quinazolines. J. Med. Chem. 1990, 33, 2045–2051.
22. Jones, T. R.; Vamey, M. D.; Webber, S. E.; Welsh, K. M.; Webber, S.; Matthews, D. A.; Appelt, K.; Smith, W. S.; Janson, C.; Bacquet, R.; Lewis, K. K.; Marzoni, G. P.; Kathardekar, V.; Howland, E.; Booth, C.; Herrmann, S.; Ward, R.; Sharp, J.; Moomaw, E.; Bartlett, C.; Morse, C. New Lipophilic Thymidylate Synthase Inhibitors Designed from the X-ray Structure of the E. coli Enzyme. Proc. Am. Assoc. Cancer Res. 1990, 31, 340.
23. Appelt, K.; Bacquet, R. J.; Bartlett, C. A.; Booth, C. L. J.; Freer, S. T.; Fuhry, M. M.; Gehring, M. R.; Herrmann, S. M.; Howland, E. F.; Janson, C. A.; Jones, T. R.; Kan, C.; Kathardekar, V.; Lewis, K. K.; Marzoni, G. P.; Matthews, D. A.; Mohr, C.; Moomaw, E. W.; Morse, C. A.; Oatley, S. J.; Ogden, R. C.; Reddy, M. R.; Reich, S. H.; Schoettlin, W. S.; Smith, W. W.; Varney, M. D.; Villafranca, J. E.; Ward, R. W.; Webber, S.; Webber, S. E.; Welsh, K. M.; White, J. Design of Enzyne Inhibitors Using Iterative Protein Crystallographic Analysis. J. Med. Chem. 1991, 34, 1925–1934.
24. Varney, M. D.; Marzoni, G. P.; Palmer, C. L.; Deal, J. G.; Webber, S.; Welsh, K. M.; Bacquet, R. J.; Bartlett, C. A.; Morse, C. A.; Booth, C. L. J.; Herrmann, S. M.; Howland, E. F.; Ward, R. W.; White, J. Crystal-Structure-Based Design and Synthesis of Benz[cd]indole-Containing Inhibitors of Thymidylate Synthase. J. Med. Chem. 1992, 35, 663–676.
25. Reich, S. H.; Fuhry, M. M.; Nguyen, D.; Pino, M. J.; Welsh, K. M.; Webber, S.; Janson, C. A.; Jordan, S. R.; Matthews, D. A.; Smith, W. W.; Bartlett, C. A.; Booth, C. L. J.; Herrmann, S. M.; Howland, E. F.; Morse, C. A.; Ward, R. W.; White, J. Design and Synthesis of Novel 6,7-Imidazotetrahydroquinoline Inhibitors of Thymidylate Synthase Using Iterative Protein Crystal Structure Analysis. J. Med. Chem. 1992, 35, 847–858.
26. Matthews, D. A.; Appelt, K.; Oatley, S. J.; Xuong, N. H. Crystal Structure of Escherichia coli Thymidylate Synthase Containing Bound 5-Fluoro-2′-Deoxyuridylate and 10-Propargyl-5,8-Dideazafolate. J. Mol. Biol. 1990, 214, 923–936.
27. The molecules were minimized using the CHARMM or AM1 programs: Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comp. Chem. 1983, 4, 187–217.
28. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902–3909.
29. Stewart, J. J. P. A Semiemperical Molecular Orbital Program. J. Comput. Aid. Mol. Design 1990, 4, 1–105.
30. 3 fragments derived from chlorobenzene and toluene are 0.71 and 0.56, respectively. See:Hansch, C.; Leo, A. J. Substituents Constants for Correlation Analysis in Chemistry and Biology; John Wiley and Son Inc.: New York, 1979.
31. Bacquet, R. J. Electrostatic Contributions to Binding Affinity for the Enzyme Thymidylate Synthase and a Seriesof Inhibitors. Submitted to Trends in QSAR and Molecular Modeling '92; Wermuth, C. G., Ed.; ESCOM: Leiden, 1992.
32. Marsham, P. R.; Chambers, P.; Hayter, A. J.; Hughes, L. R.; Jackman, A. L.; O'Connor, B. M.; Bishop, J. A. M.; Calvert, A. H. Quinazoline Antifolate Thymidylate Synthase Inhibitors: Nitrogen, Oxygen, Sulfur, and Chlorine Substituents in the C2 Position. J. Med. Chem. 1989, 32, 569–575.
33. Jones, T. R.; Thornton, T. J.; Flinn, A.; Jackman, A. L.; Newell, D. R.; Calvert, A. H. Quinazoline Antifolates Inhibiting Thymidylate Synthase: 2-Desamino Derivatives with Enhanced Solubility and Potency. J. Med. Chem. 1989, 32, 847–852.
34. 10-Propargyl-5,8-Dideazafolic Acid and Related Compounds. J. Med. Chem. 1989, 32, 1284–1289.
35. Hughes, L. R.; Jackman, A. L.; Oldfield, J.; Smith, R. C.; Burrows, K. D.; Marsham, P. R.; Bishop, J. A. M.; Jones, T. R.; O'Connor, B. M.; Calvert, A. H. Quinazoline Antifolate Thymidylate Synthase Inhibitors: Alkyl, Substituted Alkyl, and Aryl Substituents in the C2 Position. J. Med. Chem. 1990, 33, 3060–3067.
36. For a review of the Ullmann reaction, see:Moroz, A. A.; Shvarts berg, M. S. The Ullmann Ether Condensation. Russ. Chem. Rev. 1974, 43, 679–689.
37. Gilman, H., Blatt, A. H., Eds. Organic Syntheses; John Wiley and Sons Inc.: New York, 1941; Collect. Vol. I, pp 327–330.
38. Dighe, V. S.; Somasekhara, S.; Bagavant, G.; Mukherjee, S. L. 3-Aminoquinazolinones and Their Derivatives. Curr. Sci. 1964, 33, 78–80.
39. Wuest, H. M.; Sakal, E. H. Some Derivatives of 3-Pyridol with Parasympathomimetic Properties. J. Am. Chem. Soc. 1951, 73, 1210–1216.
40. Albert, A.; Barlin, G. B. Ionization Constants of Heterocyclic Substances. Part V. Mercapto-Derivatives of Diazines and Benzodiazines. J. Chem. Soc. 1962, 3129–3141.
41. For a review on Lawesson's reagent, see:Cava, M. P.; Levinson, M. I. Thionation Reactions of Lawesson's Reagents. Tetrahedron 1985, 41, 5061–5087.
42. Ochiai, E. Recent Japanese Work on the Chemistry of Pyridine-1-Oxide and Related Compounds. J. Org. Chem. 1953, 18, 534–551.
43. Den Hertog, H. J.; Van Ammers, M. The Directive Influence of the N-Oxide Group During the Nitration of Derivatives of Pyridine-N-Oxide (III). Recl. Trav. Chim. Pays-Bas 1955, 74, 1160–1166.
44. Leonard, F.; Wajngurt, A. Synthesis of Some Sulfur-Containing Derivatives of Pyridine 1-Oxide and Quinoline 1-Oxide. J. Org. Chem. 1956, 21, 1077–1081.
45. Blank, B.; DiTullio, N. W.; Miao, C. K.; Owings, F. F.; Gleason, J. G.; Ross, S. T.; Berkoff, C. E.; Saunderss, H. L. Mercaptopyridinecarboxylic Acids, Synthesis and Hypoglycemic Activity. J. Med. Chem. 1974, 17, 1065–1071.
46. Marsham, P. R.; Jackman, A. L.; Hayter, A. J.; Daw, M. R.; Snowden, J. L.; O'Connor, B. M.; Bishop, J. A. M.; Calvert, A. H.; Hughes, L. R. Quinazoline Antifolate Thymidylate Synthase Inhibitors: Bridge Modifications and Conformationally Restricted Analogues in the C2-Methyl Series. J. Med. Chem. 1991, 34, 2209–2218.
47. Melloni, G.; Modena, G. Reactivity of Vinyl Sulphonic Esters. Part X. Effect of the Substituents on the Cyclisation of Arylthiovinyl Sulphonates to Benzo[b]thiophenes. J. Chem. Soc, Perkin Trans. 1 1972, 218–221.
48. 3H. J. Biol. Chem. 1967, 242, 109–113.
49. Morrison, J. F. Kinetics of the Reversible Inhibition of Enzyme-Catalyzed Reactions by Tight-Binding Inhibitors. Biochim. Biophys. Acta 1969, 185, 269–286.
50. Alley, M. C.; Scuderio, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Schoemaker, R. H.; Boyd, M. R. Feasibility of Drug Screening with a Panel of Human Tumor Cell Lines Using a Microculture Tetrazolium Assay. Cancer Res. 1988, 48, 589–601.
51. Mosmann, T. J. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J. Immunol. Methods 1983, 65, 55–63.
52. Kindly supplied by Dr.P. J. Houghton and Dr. J. A. Houghton, St. Judes Children's Research Hospital, Memphis, TN.
53. Bodor, N.; Gabanyi, Z.; Wong, C. A New Method for the Estimation of Partition Coefficient. J. Am. Chem. Soc. 1989, 111, 3783–3786.
54. Perrella, F. W. EZ-FIT, Perrella Scientific, Springfield, PA.
55. Jackson, R. C.; Fry, D. W.; Boritzki, T. J.; Besserer, J. A.; Leopold, W. R.; Sloan, B. J.; Elslager, E. F. Biochemical Pharmacology of the Lipophilic Antifolate, Trimetrexate. In Advances in Enzyme Regulation, 22; Weber, G., Ed.; Pergaman Press: Oxford, 1984; pp 187–206.
56. Lucas, H. J.; Scudder, N. F. The Preparation of 2-Bromo-p-Cresol from p-Nitrotoluene. J. Am. Chem. Soc. 1928, 50, 244–249.
57. Venuti, M. C. Isatoic Anhydride/4-Dimethylaminopyridine as a Reagent for ortho-Aminobenzoylation. Synthesis 1982, 266–268.
58. Dreschel, E. Beitrage zur Kenntniss des Cyanamids. J. Prakt. Chem. 1875, 11, 284–353.
59. Burns, J.; McCombie, H.; Scarborough, H. A. CCCLXXXV.-Some Substitution Products of Azobenzene. J. Chem. Soc. 1928, 2928–2936.
60. Lambooy, J. P. Syntheses and Biological Activities of 7-Ethyl-8-bromo-10-(l'-D-ribityl)isoalloxazine and 7-Bromo-8-ethyl-10-(1′-d-ribityl)isoalloxazine, Analogs of Riboflavin. J.Med. Chem. 1974, 17, 227–230.
61. Suthers, B. R.; Riggins, P. H.; Pearson, D. E. The Swamping Catalyst Effect. IV. The Halogenation of Anilines. J. Org. Chem. 1962, 27, 447–451.
62. Jarvie, J. M. S.; Fitzgerald, W. E.; Janz, G. J. 2-Trifluoromethylpyridine. J. Am. Chem. Soc. 1956, 78, 978–979.